Sanofi/GSK Coronavirus Vaccine Candidate Fails To Produce Sufficient Immune Response In Older People, Delaying Trials

Reuters: Sanofi and GSK delay COVID-19 vaccine, marking setback for global fight
“Sanofi and GlaxoSmithKline said clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people, delaying its launch to late next year and marking a setback in the global fight against the pandemic. … The news, which came on the same day as Australia axed a domestic vaccine project, is also a blow for many governments that have booked hundreds of millions of doses of the shot, including the European Union, United States, and Britain. … The two companies said they planned to start another study next February, hoping to come up with a more effective vaccine by the end of 2021…” (Blamont et al., 12/11).

Additional coverage of the Sanofi/GSK vaccine candidate is available from Financial Times.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.